ArticleInternational journal of nanomedicine2026
Dual-Metal Organic Framework Nanozyme for Synergistic Photothermal-Chemodynamic Therapy: Copper-Molybdenum Synergism in Gastric Cancer Treatment.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To address the dual challenges of chemotherapy toxicity and poor tumor microenvironment regulation in gastric cancer, we developed a copper-molybdenum bimetallic organic framework nanozyme (CMP) that integrates chemodynamic therapy (CDT) and photothermal therapy (PTT). The system leverages synergistic reactive oxygen species (ROS) generation and localized hyperthermia to deliver efficient, low-toxicity treatment. Methods: The CMP nanodrug was synthesized by encapsulating Keggin-type phosphomolybdic acid (H Results: The CMP nanozyme demonstrated exceptional photothermal conversion efficiency (29.4% under 808 nm laser). In vitro experiments revealed significant cytotoxicity with ROS elevation. In vivo studies showed significant tumor growth inhibition without hematotoxicity (WBC, ALT levels showed no statistical significance vs. controls). Histopathology confirmed extensive tumor necrosis with preserved cytoarchitecture in vital organs (heart, liver, spleen, and kidney). Conclusion: The CMP nanozyme achieves potent antitumor efficacy through photothermal-enhanced Fenton-like reactions, depleting glutathione and amplifying ROS. It suppresses gastric cancer in vivo with minimal systemic toxicity, representing a promising nanoplatform for precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.